Transporter-mediated drug-drug interactions

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 4, 2011, Pages 481-484

  Zhang, L ^a   Huang, S M ^a   Lesko, L J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BREAST CANCER RESISTANCE PROTEIN; CIPROFLOXACIN; CYCLOSPORIN; DIGOXIN; DRONEDARONE; ELACRIDAR; FLUINDOSTATIN; FUROSEMIDE; GLYCOPROTEIN P; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; ITRACONAZOLE; LOPERAMIDE; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3; PITAVASTATIN; PRAVASTATIN; PROBENECID; QUINIDINE; RANOLAZINE; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; ROSUVASTATIN; SIMVASTATIN; TENOFOVIR; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

BLOOD BRAIN BARRIER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG UPTAKE; HUMAN; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW;

BINDING SITES; BIOLOGICAL TRANSPORT; DRUG INTERACTIONS; HUMANS; MEMBRANE TRANSPORT PROTEINS; PHARMACOKINETICS; PROTEIN BINDING; TISSUE DISTRIBUTION; XENOBIOTICS;

EID: 79952943003     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.359     Document Type: Review

References (5)

1. Zhang, L., Reynolds, K., Zhao, P. & Huang, S.-M. Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol. Appl. Pharmacol. 243, 134-145 (2010).
2. International Transporter Consortium (Giacomini, K.M. et al). Membrane transporters in drug development. Nat. Rev. Drug Disc. 9, 215-236 (2010).
3. Huang, S.-M., Zhang, L. & Giacomini, K.M. The International Transporter Consortium: a collaborative group of scientists from academia, Industry, And the FDA. Clin. Pharmacol. Ther. 87, 32-36 (2010).
4. Huang, S.-M. & Woodcock, J. Transporters in drug development: advancing on the Critical Path. Nat. Rev. Drug Discov. 9, 175-176 (2010).
5. Zhao, P. et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89, 259-267 (2011).